CORRESP Filing
Enveric Biosciences, Inc.
Date: April 28, 2026 · CIK: 0000890821 · Accession: 0001493152-26-019272
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295273
Letter
RE: Enveric Biosciences, Inc.
April 28, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
(File No. 333-295273)
Acceleration Request
Requested Date: April 29, 2026
Requested Time: 5:00 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”) requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Rasika A. Kulkarni of Greenberg Traurig, LLP at (650) 289-7813 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
Enveric Biosciences, Inc.
Show Raw Text
CORRESP
1
filename1.htm
April
28, 2026
VIA
EDGAR
United
States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE:
Enveric
Biosciences, Inc.
Registration
Statement on Form S-3
(File
No. 333-295273)
Acceleration
Request
Requested
Date: April 29, 2026
Requested
Time: 5:00 p.m., Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”)
requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities
and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth
above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation
Finance of the Commission.
Please
call Rasika A. Kulkarni of Greenberg Traurig, LLP at (650) 289-7813 to confirm the effectiveness of the Registration Statement or with
any questions.
Very truly yours,
Enveric Biosciences, Inc.
By:
/s/
Joseph Tucker
Name:
Joseph
Tucker, Ph.D.
Title:
Chief
Executive Officer